We are so excited to introduce our newest investment team member, Justin Feng! Justin joins us as a Senior Associate and will be spending his time building companies focused on developing novel therapeutics across multiple therapeutic areas. Welcome, Justin! Learn more about Justin here: https://lnkd.in/eHJ44fc6
Atlas Venture
风险投资与私募股权管理人
Cambridge，MA 25,195 位关注者
We build breakthrough biotech companies with remarkable life science entrepreneurs.
关于我们
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.?
- 网站
-
https://www.atlasventure.com
Atlas Venture的外部链接
- 所属行业
- 风险投资与私募股权管理人
- 规模
- 11-50 人
- 总部
- Cambridge，MA
- 类型
- 合营企业
- 创立
- 1984
- 领域
- Biotech和Venture Capital
地点
-
主要
获取路线
300 Technology Square
US，MA，Cambridge，02139
Atlas Venture员工
动态
-
#Science2Startup has extended their submission deadline to December 2nd! Learn more and submit your proposal here: https://lnkd.in/ei5r_iM
-
-
We are inspired by the mission of Eric Green & the team at Trace Neuroscience in their pursuit of genomic therapies for patients with neurodegenerative diseases including ALS. We are thrilled to partner with them on this journey. #doingwellbydoinggood
Did you know approximately 30,000 people in the U.S. are living with amyotrophic lateral sclerosis, and 1 in 400 people around the world will be diagnosed with #ALS during their lifetime? Introducing Trace Neuroscience, a company built on scientific breakthroughs?with a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases, starting with ALS. Our initial focus is developing a?novel genomic therapy that restores UNC13A protein to re-establish healthy communication between nerves and muscle cells, to improve muscle function and quality of life, slow disease progression and extend survival.?Learn more:?https://lnkd.in/eAQJW7Qc
-
Time is running out! #Science2Startup 2025, on Wednesday, May 14th, is a one-day symposium providing research applicants with a unique opportunity to receive guidance and mentorship from leaders in the biotech field. Submit your application by Friday, November 15th, to pitch your innovative startup ideas to leading #biotech and #pharma experts: https://lnkd.in/e7bPwMzX
-
-
An exciting day for all involved at Rectify Pharma as they announce selection of their lead small molecule #PFM for treatment of hepatobiliary diseases. Congrats to the team!
-
An exciting day at TRIANA Biomedicines as they announce their research collaboration with Pfizer. TRIANA is focused on building a target-first molecular glue discovery pipeline for difficult to address disease targets. Congratulations to the teams!
Big news today for TRIANA! Announcing a research collaboration with Pfizer to Discover?novel molecular glue degraders https://lnkd.in/exAGkn68
-
-
Join us and other host firms F-Prime Capital, 5AM Ventures, Osage University Partners (OUP), and RA Capital Management, for the 2025 #Science2Startup symposium! This year's event is set for Wednesday, May 14th, featuring top scientists presenting to an audience of leading #biotech and #pharma executives, VCs, and entrepreneurs. Have a groundbreaking idea for a biotech #startup? Submit your application by Friday, November 15th: https://lnkd.in/e7bPwMzX
Home - Science to Startup
https://www.science2startup.com
-
Congratulations to the Judo team on their launch today! It has been a privilege to build Judo alongside Atlas and TCG over the past three years, and I’m especially grateful for the support from Kevin Bitterman and Jeff Goater. The journey from concept to a well-tuned engine on its way to the clinic, with a stellar team and strong financing, hasn’t always been easy—but seeing all the pieces come together now is incredibly exciting. This is just the beginning and the future looks bright with Rajiv Patni and Alfica Sehgal leading the way! https://judo.bio/ https://lnkd.in/ep9xqFP7
Breaking through to the Kidney - Judo Bio
https://judo.bio
-
Wonderful to see Allison August, M.D., Chief Medical Officer at Comanche Biopharma recognized on this impressive list! Congratulations!
Congratulations to our Chief Medical Officer Allison August, M.D. for being featured by Endpoints News in its Women in Biopharma 2024 Special Report, which highlights 20 women who are breaking new ground in #biopharma R&D. Our mission at Comanche is to develop and make globally available the first treatment targeting a root cause of preeclampsia. As CMO, Allison is overseeing the clinical development of CBP-4888, our investigational #siRNA therapy that targets an underlying cause of preeclampsia, overproduction of the protein sFlt1 in the placenta. Allison brings a unique blend of maternal health expertise as an obstetrician-gynecologist, robust clinical development experience, profound intellect, inspiring leadership, incredible grit, and unwavering compassion for patients.?We are so honored to work with her every day! Read more about Allison and the other trailblazing women in biopharma R&D featured in this year's report: https://bit.ly/3BBC7dA #MaternalHealth #preeclampsia
-
-
A wonderful start to the week for Judo Bio as they officially launch with $100M in funding! Judo has discovered a novel approach to create oligonucleotide medicines targeted to the kidney, an organ that has been challenging to access for genetic medicines.?Congrats to the Judo team! #doingwellbydoinggood
Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO - Judo Bio
https://judo.bio